Voronoi, Inc. (KOSDAQ:310210)

South Korea flag South Korea · Delayed Price · Currency is KRW
238,000
+6,000 (2.59%)
At close: Dec 5, 2025
193.83%
Market Cap 4.28T
Revenue (ttm) 7.49B
Net Income (ttm) -47.26B
Shares Out 17.99M
EPS (ttm) -2,628.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 215,322
Average Volume 128,475
Open 236,000
Previous Close 232,000
Day's Range 219,000 - 242,000
52-Week Range 68,000 - 255,500
Beta 1.93
RSI 57.92
Earnings Date Nov 13, 2025

About Voronoi

Voronoi, Inc. researches, develops, and discovers small molecule kinase inhibitors in South Korea. Its products pipeline includes VRN01, an oral leucine rich repeat kinase 2 inhibitor targeting glioblastoma multiforme to treat brain and pancreatic cancers; VRN07, VRN06, and VRN11 for the treatment of lung cancer; VRN08 and VRN10 to treat breast cancer; and VRN02 for the treatment of rheumatoid arthritis and atopic dermatitis. The company’s products pipeline also comprise VRN04-1 to treat autoimmune diseases; VRN04-2 for the treatment of multipl... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 140
Stock Exchange KOSDAQ
Ticker Symbol 310210
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.